Cardiac Amyloidosis in Patients With Aortic Stenosis

Sponsor
Shanghai Zhongshan Hospital
Study ID
NCT07170306
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
65 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • transcatheter aortic valve replacement (TAVR) — PROCEDURE
    TAVR is a minimally invasive cardiac interventional procedure that delivers a compressed artificial aortic valve to the diseased aortic valve site via peripheral blood vessels (e.g., the femoral artery) or the apex of the heart through a catheter, releases and deploys the valve to replace the original diseased valve leaflets, thereby restoring normal valve function and treating severe aortic stenosis (AS).

Study Details

This study intends to conduct a prospective observation to investigate the prevalence of cardiac amyloidosis (CA) in patients with aortic stenosis (AS), compare the clinical characteristics between patients with isolated AS and those with AS complicated by CA (CA-AS), and simultaneously explore the impact of transcatheter aortic valve replacement (TAVR) on serum transthyretin (TTR) levels in patients with AS complicated by transthyretin amyloidosis (ATTR-AS), as well as its influence on the treatment outcomes of patients with isolated AS and ATTR-AS.

Key Dates

Start date
Jan 31, 2026
Status verified
Jan 2026
Primary completion
May 31, 2028
Completion
May 31, 2028

Study Design

Enrollment
143 participants (estimated)

Arms

  • Arm: ATTR-AS group
    Patients were grouped according to the presence or absence of ATTR, i.e., into the isolated AS group and the ATTR-AS group.
  • Arm: AS group
    Patients were grouped according to the presence or absence of ATTR, i.e., into the isolated AS group and the ATTR-AS group.

Primary Outcome Measure

All-cause mortality Composite endpoint of death and first hospitalization for heart failure In accordance with [ Time Frame: baseline, 1 month, 3 months, 6 months, and 12 months ]

Central Contacts

Related Studies